title: L11. Hepatitis C virus mixed cryoglobulinemia vasculitis: therapeutic options.
authors: Université Pierre-et-Marie-Curie-Paris-6, UMR 7211 (CNRS/UPMC) Inserm U959, AP-HP, hôpital Pitié-Salpêtrière, service de médecine interne, 75013 Paris, France. patrice.cacoub@psl.aphp.fr
authors: Patrice
authors: P
authors: Cacoub
authors: Benjamin
authors: B
authors: Terrier
authors: David
authors: D
authors: Saadoun
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000009:adverse effects / Q000627:therapeutic use; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001402:B-Lymphocytes / Q000187:drug effects; D001781:Blood Component Removal; D003131:Combined Modality Therapy; D003449:Cryoglobulinemia / Q000188:drug therapy* / Q000276:immunology / Q000821:virology*; D004359:Drug Therapy, Combination; D016174:Hepacivirus / Q000187:drug effects / Q000472:pathogenicity*; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000276:immunology* / Q000821:virology*; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use; D010956:Plasmapheresis; D011092:Polyethylene Glycols / Q000009:adverse effects / Q000627:therapeutic use; D011480:Protease Inhibitors / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D012254:Ribavirin / Q000009:adverse effects / Q000627:therapeutic use; D000069283:Rituximab
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000998:Antiviral Agents; D007155:Immunologic Factors; D007166:Immunosuppressive Agents; D016898:Interferon-alpha; D011480:Protease Inhibitors; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; D000069283:Rituximab; C100416:peginterferon alfa-2a